Royce & Associates LP purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 20,000 shares of the medical equipment provider’s stock, valued at approximately $908,000.
Several other large investors have also modified their holdings of the company. Great Lakes Advisors LLC grew its position in Hologic by 14.6% during the second quarter. Great Lakes Advisors LLC now owns 99,268 shares of the medical equipment provider’s stock worth $4,505,000 after buying an additional 12,681 shares in the last quarter. Cutter & CO Brokerage Inc. grew its position in Hologic by 1.7% during the second quarter. Cutter & CO Brokerage Inc. now owns 11,530 shares of the medical equipment provider’s stock worth $523,000 after buying an additional 190 shares in the last quarter. Essex Financial Services Inc. acquired a new stake in Hologic during the second quarter worth about $259,000. Meiji Yasuda Asset Management Co Ltd. grew its position in Hologic by 11.1% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 14,047 shares of the medical equipment provider’s stock worth $637,000 after buying an additional 1,400 shares in the last quarter. Finally, Stanley Laman Group Ltd. grew its position in Hologic by 1.9% during the second quarter. Stanley Laman Group Ltd. now owns 105,809 shares of the medical equipment provider’s stock worth $4,802,000 after buying an additional 1,950 shares in the last quarter. 96.39% of the stock is currently owned by institutional investors.
Hologic, Inc. (HOLX) opened at 37.72 on Friday. The company has a 50-day moving average of $38.90 and a 200 day moving average of $42.58. Hologic, Inc. has a 52-week low of $35.15 and a 52-week high of $46.80. The company has a market cap of $10.58 billion, a PE ratio of 14.05 and a beta of 0.92.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million during the quarter, compared to the consensus estimate of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.51 EPS. Equities research analysts predict that Hologic, Inc. will post $2.01 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Royce & Associates LP Purchases New Stake in Hologic, Inc. (HOLX)” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/17/royce-associates-lp-purchases-new-stake-in-hologic-inc-holx.html.
A number of equities research analysts recently weighed in on HOLX shares. Zacks Investment Research downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Jefferies Group LLC set a $49.00 target price on Hologic and gave the stock a “buy” rating in a research report on Sunday, May 28th. Stifel Nicolaus reissued a “buy” rating on shares of Hologic in a research report on Friday, July 14th. Piper Jaffray Companies reissued a “buy” rating and set a $51.00 target price on shares of Hologic in a research report on Friday, July 14th. Finally, Barclays PLC reissued an “overweight” rating and set a $53.00 target price (up from $50.00) on shares of Hologic in a research report on Monday, July 17th. One analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company. Hologic presently has a consensus rating of “Buy” and a consensus price target of $48.64.
In related news, Director Elaine Ullian sold 8,849 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $45.28, for a total value of $400,682.72. Following the completion of the transaction, the director now owns 23,810 shares of the company’s stock, valued at approximately $1,078,116.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Lawrence M. Levy sold 7,139 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $39.04, for a total transaction of $278,706.56. The disclosure for this sale can be found here. In the last three months, insiders sold 27,594 shares of company stock valued at $1,168,871. 0.79% of the stock is owned by insiders.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.